Novel JAK1 Inhibitor Reduced Treatment Failures in Active Noninfectious Uveitis
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, ...
Read moreDetails